Gosset Ownership
Private
Employees
~11
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Calypso Biotech General Information
Calypso Biotech's lead product CALY-002 is a best-in-class anti-IL-15 antibody currently in Phase 1 trials. The company has completed the healthy volunteers phase showing favorable safety data and differentiating target engagement biomarker data. CALY-002 is the first IL-15-specific antibody to demonstrate blood NK cell reduction in humans. The company is on track for top-line histology data in Celiac Disease and Eosinophilic Esophagitis, and has shown proof-of-concept data in a humanized Atopic Dermatitis model.[6][3]
Contact Information
Primary Industry
Biotech
Corporate Office
Amsterdam, North Holland
Netherlands
Netherlands
Drug Pipeline
CALY-002
Phase 1Key Partnerships
Calypso Biotech Funding
No funding data available
To view Calypso Biotech's complete valuation and funding history, request access »